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Anti-AMPA GluA3 antibodies in 
Frontotemporal dementia: a new 
molecular target
B. Borroni1, J. Stanic  2, C. Verpelli3, M. Mellone2, E. Bonomi1, A. Alberici1, P. Bernasconi4,  
L. Culotta3, E. Zianni2, S. Archetti5, M. Manes1, S. Gazzina1, R. Ghidoni6, L. Benussi  6,  
C. Stuani7, M. Di Luca2, C. Sala3, E. Buratti7, A. Padovani1 & F. Gardoni2
Frontotemporal Dementia (FTD) is a neurodegenerative disorder mainly characterised by Tau or 
TDP43 inclusions. A co-autoimmune aetiology has been hypothesised. In this study, we aimed at 
defining the pathogenetic role of anti-AMPA GluA3 antibodies in FTD. Serum and cerebrospinal fluid 
(CSF) anti-GluA3 antibody dosage was carried out and the effect of CSF with and without anti-GluA3 
antibodies was tested in rat hippocampal neuronal primary cultures and in differentiated neurons 
from human induced pluripotent stem cells (hiPSCs). TDP43 and Tau expression in hiPSCs exposed to 
CSF was assayed. Forty-one out of 175 screened FTD sera were positive for the presence of anti-GluA3 
antibodies (23.4%). FTD patients with anti-GluA3 antibodies more often presented presenile onset, 
behavioural variant FTD with bitemporal atrophy. Incubation of rat hippocampal neuronal primary 
cultures with CSF with anti-GluA3 antibodies led to a decrease of GluA3 subunit synaptic localization of 
the AMPA receptor (AMPAR) and loss of dendritic spines. These results were confirmed in differentiated 
neurons from hiPSCs, with a significant reduction of the GluA3 subunit in the postsynaptic fraction 
along with increased levels of neuronal Tau. In conclusion, autoimmune mechanism might represent a 
new potentially treatable target in FTD and might open new lights in the disease underpinnings.
Frontotemporal Dementia (FTD) is a neurodegenerative disorder characterized by behavioural abnormalities, 
language impairment, and deficits of executive functions1,2. FTD is clinically heterogeneous, behavioural variant 
FTD (bvFTD) and Primary Progressive Aphasias (PPAs) representing the most common phenotypes1,2 and being 
characterized by frontotemporal atrophy, often asymmetric3.
In the last ten years, research in FTD field has witnessed a giant step forward in defining the pathogenetic 
bases of the disease4. The identification of mutations responsible of autosomal dominant inherited disorder, 
namely Microtuble Associated Protein Tau (MAPT), Granulin (GRN) and chromosome 9 open reading frame 72 
(C9orf72) mutations, has further elucidated the molecular pathways involved in brain depositions of either Tau 
or TAR DNA-binding protein 43 (TDP43) inclusions5. In FTD cases associated with pathogenic mutations in 
MAPT, the Tau accumulation in neurons and glia has been explained in terms of abnormal phosphorylation of 
the protein, or an altered proportion in the production ratio of the 4R and 3R Tau isoforms6; conversely, GRN 
mutation haploinsufficiency and C9orf72 expansion lead to TDP43 aggregation, with a less defined mechanism7,8. 
However, for the majority of FTD patients without known pathogenic mutations, the molecular pathways related 
to either Tau or TDP43 protein aggregations are still uncovered. Furthermore, no clinical or neuroimaging data 
can clearly predict neuropathological trait in FTD patients without pathogenic mutations, and it is unknown 
whether Tau and TDP43 unfolding represents the primary pathogenic mechanism or whether this might be trig-
gered by external and still undetermined factors.
At present, no risk factors but genetic background have been recognised in FTD. Notwithstanding this 
absence, an inflammatory contribution to general neurodegenerative disease pathogenesis has long been 
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hypothesized on the basis of large epidemiological studies9. In particular, a significantly increased risk of auto-
immune disorders represented by inflammatory arthritis, cutaneous disorders, and gastrointestinal conditions 
has been found in the PPAs along with an elevation of TNF-α levels10. Interesting hints have been provided by 
studies on FTD language variants, in which an autoimmune process was postulated for some cases11. Moreover, 
genome-wide association analysis (GWAS) in FTD found a significant enrichment for elements of immune sys-
tem involved in antigen presentation, such as HLA-DR5 locus12.
Altogether, these findings argue for a potential role exerted by dysregulation of the immune homeostasis in 
FTD, even though the key-elements are undefined. Recently, we identified anti- α-amino-3-hydroxy-5-methyl
-4-isoxazolepropionic acid receptor (AMPAR) antibodies, namely GluA3 subunit autoantibodies, in a few FTD 
cases screened at our centre13. This evidence, along with the recognised central role of AMPARs in regulating Tau 
processing14 and the presence of asymmetric frontotemporal atrophy in autoimmune encephalitis associated with 
anti-GluA3 antibodies15,16, prompted the present study.
In this work, we carried out a screening of GluA3 autoantibodies in a large series of FTD patients and the neu-
robiological effect of anti-GluA3 autoantibodies was investigated in rat hippocampal neuronal primary cultures 
and in neurons differentiated from human induced pluripotent stem cells (hiPSCs).
Methods
Setting and participants. Patients fulfilling criteria for FTD1,2 were consecutively recruited from the 
Centre for Neurodegenerative Disorders, University of Brescia, Italy. FTD diagnosis was accomplished by exten-
sive neuropsychological assessment and the presence of frontotemporal atrophy at brain MRI scan.
Only patients with available blood sampling and those with no mutations within GRN, MAPT, or C9orf72 
genes were considered in the present study.
Demographic characteristics were carefully recorded. Diagnosis of bvFTD and PPA was further considered1,2. 
A positive family history suggestive for autosomal dominant disorder was defined in cases with three subjects 
across two generations with symptoms of dementia, psychiatric illness, or motor neuron disease17. The presence 
of known autoimmune disorder was assessed by a brief interview.
Neuroimaging features were analysed by means of Voxel-Based Morphometry (VBM, SPM12 software pack-
age Wellcome Department of Imaging Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm).
Moreover, 60 healthy controls recruited among spouses and healthy volunteers and aged- and gender-matched 
with FTD sample, were included in order to set up the cut-off score of anti-GluA3 antibody levels18. Twenty-five 
control subjects who underwent lumbar puncture for headache or chronic neuroapathy and age-matched with 
FTD sample, were included to test anti-GluA3 antibody levels and cut-off in cerebrospinal fluid (CSF).
For all participants, informed consent in the study was obtained according to sampling protocols that were 
approved by Ethics Committee of Brescia Hospital, Italy. The study was conducted in accordance with the 
Helsinki Declaration.
Serum dosage of anti-GluA3 antibody levels. Serum samples were frozen immediately after centrifu-
gation and stored at −20 °C pending enzyme-linked immunosorbent assay (ELISA). The detection of anti-GluA3 
antibodies (peptide A and peptide B) was performed by ELISA according to previously published protocol18, with 
minor modifications.
Peptide synthesized by Biomatik Company (Cambridge, UK), corresponding to portions of the human GluA3 
protein (GenBank accession number P42263), were used: (i) NNENPMVQQFIQRWVRLDEREFPEAKNAP 
(GluA3 peptide A, amino acids 274–302) and (ii) NEYERFVPFSDQQISNDSASSENRT (GluA3 peptide B, amino 
acids 399–424). Comparison of the two peptides between human and rat GluA3 indicated a 98% homology.
According to literature data, there is a clear-cut relationship between anti-GluA3 peptide A antibody and 
anti-GluA3 peptide B antibody dosages18; for the purpose of the present study, we measured anti-GluA3 pep-
tide A antibodies in all samples and anti-GluA3 peptide B antibodies in a subset of samples to further prove the 
association.
Nunc-immuno microtiter 96-well plates (Thermo Scientific, Denmark) were coated with 100 μl of 20 μg/
ml of free peptide in phosphate buffered saline (PBS) plus 0.05% Tween 20 overnight at 4 °C. Wells were then 
treated after blocking buffer (PBS plus 10% bovine serum albumin-BSA), and 100 μl/well of serum (dilution 
1:10), tested in duplicate, was added and incubated for 2 hours at 37 °C. After extensive washes, horserad-
ish peroxidase-conjugated rabbit anti-human IgG antibody (Sigma, Germany) was added (dilution 1:5000) 
and detection was performed with 100 μl of substrate (Tetramethylbenzidine reagent, TMB). Background was 
measured as optical density (OD) at 450 nm from wells where no serum was added, and subtracted from each 
measurement.
Inter-assay variability of anti-GluA3 peptide A antibody was less than 15% (correlation analysis = 99.5); 
Cronbach’s alpha for intra-assay variability was 0.93 (performed on 40 samples).
CSF analyses. Lumbar puncture was performed in a subset of FTD patients according to a standardized 
protocol, in the outpatient clinic, at fasting, from 9.00 a.m. to 10.00 a.m, after informed written consent. CSF was 
collected in sterile polypropylene tubes and gently mixed to avoid gradient effects. Routine chemical measures 
were determined. CSF total-Tau, phospho-Tau and Abeta 42 concentrations were measured in duplicate by ELISA 
test (Innotest hTau Antigen kit and Innotest PHOSHO-TAU 181P, Innogenetics, Ghent, Belgium).
The remaining CSF was stored at −80 °C or in liquid nitrogen for subsequent anti-GluA3 antibody dosage. 
The same protocol used for serum was applied to test anti-GluA3 antibody peptide A, except for plates (Immulon 
4HBX 96-well plates, Dynatech, Germany) and the working dilution (1:2 for CSF and 1:4500 for the secondary 
antibody).
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Confocal imaging. COS7 cells were cultured in Dulbecco’s Modified Eagle’s Medium containing Glutamax 
(DMEM + Glutamax, Thermo Scientific) supplemented with 10% Fetal Bovine Serum (Euroclone) and 
penicillin-streptomycin (Thermo Scientific). The day before transfection, COS7 cells were plated in a 12-wells 
multiwall plate and transfection of rat or human GluA3-GFP (1 μg DNA) was carried out with lipofectamine 
LTXTM method (Thermo Scientific). 36 hours after transfection COS-7 cells were fixed with 4% Paraformaldehyde 
(PFA)-4% sucrose in PBS solution for 10 minutes at 4 °C and permeabilized with 0.1% Triton-X-100 in PBS for 
15 min at room temperature (RT). After blocking in 5% BSA in PBS for 30 min at RT, cells were incubated with 
anti-GFP and with anti-GluA3 antibody (Millipore, MAB5416) or with CSF+ or CSF− samples overnight at RT. 
Cells were then washed in PBS and incubated with secondary antibodies for 1 h at RT. After washes in PBS cov-
erslips were mounted on glass slides with Fluoromount mounting medium (Sigma-Aldrich, St Louis, MO, USA).
Hippocampal neuronal primary cultures were prepared from embryonic day 18 rat hippocampi as described 
previously19. Experiments were performed by using CSF from 6 patients (3 CSF+ and 3 CSF− samples). In par-
ticular, we selected 3 CSF+ samples from patients with high concentration of the GluA3 antibody as measured 
with the Elisa assay (i.e., optical density 450 nm >0.1).
To analyse dendritic spine density, neurons were transfected at 8 days in vitro (DIV8) with GFP using the 
calcium–phosphate method. Neurons were incubated at DIV14 with CSF with anti-GluA3 antibodies (CSF+) or 
CSF without anti-GluA3 antibodies (CSF−) at 1:20 or 1:100 dilution for 24 h.
Neurons were then fixed for 5 min in 4% paraformaldehyde - 4% sucrose at 4 °C, permeabilized with 0.1% 
Triton-X-100 in PBS for 15 min at room temperature and immunostained for GFP; primary and secondary anti-
bodies were applied in 5% BSA-PBS. Cells were chosen randomly for quantification from four different coverslips. 
Fluorescence images were acquired by using the confocal LSM510 Meta system (Zeiss) with a 63x objective and a 
sequential acquisition setting at 1024 × 1024 pixel resolution; for each image, three to four sections were acquired, 
and z-projection was obtained. Analysis of dendritic spine density was performed with ImageJ software.
For colocalization studies, hippocampal neurons (DIV14) were incubated with CSF+ or CSF− anti-GluA3 
antibodies at 1:20 or 1:100 dilution for 24 h, fixed for 5 min in 4% paraformaldehyde - 4% sucrose at 4 °C, per-
meabilized with 0.1% Triton-X-100 in PBS for 15 min at room temperature and immunostained for GluA3 and 
PSD-95, a the postsynaptic marker; primary and secondary antibodies were applied in 5% BSA-PBS. Cells were 
chosen randomly for quantification from four different coverslips.
All fluorescence images were acquired by using the confocal LSM510 Meta system (Zeiss) with a 63x objective 
and a sequential acquisition setting at 1024 × 1024 pixel resolution; colocalization analysis was performed with 
the confocal software (Zeiss).
Preparation and neuronal differentiation of human iPS cells. Human blood sample was collected 
according to a clinical protocol approved by the local Bioethical Committees of different medical centres. 
Participating individuals have been informed of the objectives of the study and have signed an informed consent 
before inclusion in the study. Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll and growth 
in StemPro®-34 SFM Medium (ThermoFisher), supplemented with L-Glutamine (2 mM, Euroclone), PenStrep 
(1%, ThermoFisher), SCF (100 ng/mL, ThermoFisher), FLT-3 (100 ng/mL, ThermoFisher), IL-3 (20 ng/mL, 
ThermoFisher), IL-6 (20 ng/mL, ThermoFisher). To generate iPSC, PBMCs were transduced with 2.0 Sendai virus 
particles containing four Yamanaka factors using the integration-free CytoTune-iPS Sendai Reprogramming Kit 
(ThermoFisher). After seven days, transduced cells were plated on matrigel-coated cultures dishes and grown 
with Essential 8 medium (ThermoFisher). Three to four weeks after transduction iPSC colonies were picked and 
transferred onto matrigel-coated culture dishes (Corning) for further expansion or analysis. Immunofluorescence 
and RT-PCR experiments were performed to detect pluripotency markers (Oct 3/4, Lin28, Nanog.and Sox2). 
Then iPSCs were differentiated to neural precursors (hNPs) via embryoid body method20,21. To obtain termi-
nally differentiated neurons, proliferating hNSCs were plated in Neurobasal medium supplemented with B27 w/o 
vitA (2%, ThermoFisher), PenStrep (1%, ThermoFisher), Glutamax (2 mM, ThermoFisher), NT-3 (10 ng/mL, 
Miltenyi Biotec), BDNF (10ng/mL, Miltenyi Biotec), GDNF (10 ng/ml, Miltenyi Biotec), Retinoic Acid (1 uM, 
Sigma-Aldrich) and growth for 50 days. Medium was changed every 2–3 days thereafter.
Western blot (WB) analysis. WB analysis was performed in total cell homogenate and in Triton insoluble 
postsynaptic fractions (TIF) purified from hiPSCs differentiated neurons. To purify the TIF, neuronal homoge-
nates were centrifuged at 13,000 g for 15 min at 4 °C. The resulting pellet was resuspended in 150 mM KCl, 0.5% 
Triton and spun at 100000 g for 1 h at 4 °C. The final pellet (TIF) was homogenized with a glass-glass potter in 
20 mM Hepes buffer containing a protease inhibitor cocktail (CompleteTM).
Protein samples were separated onto an acrylamide/bisacrylamide gel at the appropriate concentration, trans-
ferred to a nitrocellulose membrane and immunoblotted with the appropriate primary and HRP-conjugated 
secondary antibodies. Membrane development was performed with the reagent Clarity Western ECL Substrate 
(Bio-Rad) or LiteAblot TURBO (Euroclone) and labelling was visualized by Chemidoc Imaging System and 
ImageLab software (Bio-Rad). For quantification, each protein was normalized against the corresponding tubu-
lin band.
For WB analysis, the following unconjugated primary antibodies were used: polyclonal anti-GluA3 antibody 
[Synaptic System - #182 203, recognizing the aa861–870 domain of the GluA3 C-tail, thus distant from the two 
domain (aa274–302 and aa399–402) recognized by the human antibody present in the CSF+ samples]; pol-
yclonal anti-GluA1 antibody (Merck Millipore); monoclonal anti-PSD-95 antibody (NeuroMab); monoclonal 
anti-tubulin antibody (Sigma-Aldrich).
WB analysis was then performed in differentiated neuron total cell lysate to evaluate Tau and TDP43 expres-
sion, and unconjugated primary antibodies were used as follows: polyclonal Tau-5 antibody (Thermofisher) and 
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polyclonal TDP43 antibody (Proteintech); for quantification, each protein was normalized against the corre-
sponding GAPDH band (G9 antibody; Santa Cruz).
Statistical analysis. Demographic and clinical characteristics between groups were analysed by using 
Student’s t-test or Chi-Square Test, as appropriate. Spearman’s correlation analysis was carried out. Results were 
expressed as mean ± standard deviation (SD). Statistical threshold was fixed at p ≤ 0.05; data analyses were per-
formed using SPSS (version 24; SPSS, Chicago, IL).
Statistical evaluations of confocal imaging studies were performed by one-way ANOVA followed by Tukey as 
post hoc test. When appropriate, experiments were performed in blind conditions. Quantification of WB analysis 
was performed by means of computer-assisted imaging (Chemidoc) after normalization on tubulin levels. All the 
group values were expressed as mean ± standard error (SEM). Comparisons between groups were performed by 
two-tailed unpaired Student’s t-test. Significance levels were defined as *p < 0.05, **p < 0.01, and ***p < 0.001; 
statistical analyses were performed using the GraphPad Prism statistical package (GraphPad software, La Jolla, 
CA, USA).
In human differentiated neurons, Tau and TDP43 levels were evaluated after normalization on GAPDH levels 
by paired Student’s t-test and significance set at *p < 0.05; statistical analyses were performed using SPSS software 
(version 21, SPSS, Inc., Chicago, IL, USA).
Results
Anti-GluA3 antibodies and related features in FTD patients. One hundred seventy-five FTD 
patients were consecutively recruited, according to inclusion and exclusion criteria (age: 65.7 ± 7.2 years, female 
40.6%), and their serum and CSF tested for the presence of anti-GluA3 antibodies and compared to those of 
healthy controls (mean age: 62.1 ± 11.0 years, female: 63.7%).
Serum anti-GluA3 peptide A antibody dosage was significantly higher in FTD patients (0.41 ± 0.03 OD 
450 nm) as compared to healthy controls (0.22 ± 0.14 OD 450 nm) (P < 0.001).
According to literature data18, the cut-off score to establish positive anti-GluA3 antibody dosage was calcu-
lated evaluating the mean of GluA3 antibody dosage in healthy controls plus 3 standard deviations; thus, the 
cut-off score was set at 0.64, (=0.22 + 3*0.14). At this established cut-off score, 23.4% of FTD patients (41/175) 
were positive for serum anti-GluA3 peptide A antibodies. None of the control subjects resulted above the cut-off 
score.
Serum anti-GluA3 peptide A antibody dosage significantly correlated with serum anti-GluA3 peptide B anti-
body dosage (n = 47, p < 0.001, Spearman’s rho correlation coefficient = 0.845) and CSF anti-GluA3 peptide A 
dosage (n = 69, p = 0.001, Spearman’s rho correlation coefficient = 0.446) (see Supplementary Figure 1).
FTD patients with anti-GluA3 antibody had presenile onset (<65 y/o) in 66% of the cases (27/41), 63.4% pre-
sented bvFTD (26/41) and 95.2% had no evidence of autosomal dominant inheritance (39/41).
No significant clinical differences between FTD patients with and without anti-GluA3 antibodies were found 
(see Table 1). However, a significant inverse correlation between anti-GluA3 antibody dosage and age at onset 
was demonstrated, the higher the serum of anti-GluA3 antibody dosage the lower the age at onset (p = 0.041, 
Spearman correlation coefficient = −0.155; see Fig. 1). None of FTD patients with anti-GluA3 antibodies pre-
sented a positive family history for autoimmune disorders.
FTD patients with anti-GluA3 antibodies did not differ in CSF Tau and phospho-Tau levels as compared to 
patients without anti-GluA3 antibodies (see Table 1).
FTD patients with anti-GluA3 antibodies presented bitemporal atrophy at MRI scan (see Fig. 2); no significant 
neuroimaging differences between FTD patients with and without anti-GluA3 antibodies were found (data not 
shown).
In regard to CSF GluA3 antibody detection, the cut-off score was set at 0.019 (mean plus 3 standard devia-
tion = 0.004 + 3*0.005), according to values obtained in 25 control subjects (age: 72.2 ± 4.8 years, female 28%). 
None control subject resulted above the cut-off score.
Variable FTD (all) FTD-GluA3+ FTD-GluA3− P*
Number 175 41 134
Age onset, y 62.9 ± 7.0 62.1 ± 7.5 63.2 ± 6.8 n.s.
Age at diagnosis, y 65.7 ± 7.2 64.8 ± 7.7 65.9 ± 7.1 n.s.
Sex, F% 40.6 (71) 34.1 (14) 42.5 (57) n.s.
FH (AD), % 7.4 (13) 4.8 (2) 8.2 (11) n.s.
Education, y 8.9 ± 4.3 9.1 ± 4.0 8.8 ± 4.3 n.s.
bvFTD, % 70.9 (124) 63.4 (26) 73.1 (98) n.s.
CSF Abeta (pg/ml) 839.3 ± 404.5 779.2 ± 339.3 859.9 ± 425.0 n.s.
CSF Tau (pg/ml) 403.4 ± 278.5 332.4 ± 241.5 426.3 ± 287.3 n.s.
CSF pTau (pg/ml) 61.2 ± 59.4 48.9 ± 31.4 65.1 ± 65.5 n.s.
Table 1. Demographic and clinical characteristics of FTD patients according to serum anti-GluA3 antibody 
dosage. FTD: Frontotemporal dementia; GluA3+: patients with anti-GluA3 antibodies; GluA3−: patients 
without anti-GluA3 antibodies; y: years; F: female; FH (AD): autosomal dominant family history; bvFTD: 
behavioural variant FTD; CSF: cerebrospinal fluid. *P-values between GluA3+ vs. GluA3−; n.s.: not significant.
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Out of 69 FTD patients who underwent CSF analysis, 15 resulted above the cut-off scores (21.7%), with sig-
nificant correlation between serum anti-GluA3 peptide A antibody dosage and CSF anti-GluA3 peptide A dosage 
(p = 0.001, Spearman’s rho correlation coefficient = 0.446) (see Supplementary Figure 1).
A cell-based assay was used to further confirm the presence of GluA3 antibodies in CSF (see Fig. 3). CSF 
with (CSF+) or without (CSF−) anti-GluA3 antibodies were used as source of primary antibodies in confocal 
imaging studies performed in heterologous COS7 cells (not expressing endogenous AMPA receptors) transfected 
with GluA3-GFP (rat or human sequence). Incubation of COS7 cells with CSF+ lead to a specific staining of 
cells transfected with rat GluA3-GFP (Fig. 3, middle panel) similar to what has been observed with the use of 
an anti-GluA3 commercial antibody (Fig. 3, upper panel). Incubation with CSF− did not produce any signal in 
GFP-GluA3 transfected cells (Fig. 3, lower panel) thus indicating the presence of anti-GluA3 antibodies only 
in CSF+ samples. The same results were obtained by using the human GluA3-GFP plasmid (Supplementary 
Figure 2).
In vitro effect of anti-GluA3 antibodies. Two different experimental approaches were used to evaluate 
possible detrimental effects at neuronal level induced by the presence of GluA3 antibodies in the CSF. In par-
ticular, CSF+ or CSF− were added for 24 h to rat primary hippocampal neurons (DIV14) and to differentiated 
neurons from hiPSCs.
Rat primary hippocampal neurons. Treatment of rat primary hippocampal neurons (DIV14) with CSF (1:20 and 
1:100 dilution) containing anti-GluA3 antibodies (CSF+, Fig. 4A,B) led to a significant decrease of the GluA3 
subunit levels at postsynaptic sites, as indicated by the reduction of GluA3 co-localization with the postsynaptic 
marker PSD-95. Conversely, incubation with CSF lacking the anti-GluA3 antibodies (CSF−, Fig. 4A,B) did not 
induce any effect on GluA3 co-localization with PSD-95 (***p < 0.001 one-way ANOVA; Tukey post hoc test, 
mock vs. CSF+ 1:100: ***p < 0.001, mock vs. CSF+ 1:20: **p < 0.01, CSF+ 1:20 vs. CSF− 1:20: *p < 0.05, CSF+ 
1:100 vs. CSF− 1:100: *p < 0.05). Interestingly, treatment with CSF+ or CSF− did not induce any modification 
of GluA3 clusters density thus suggesting that GluA3 antibodies specifically reduce GluA3 postsynaptic levels but 
not GluA3 total levels along dendrites (Fig. 4A,C).
Figure 1. Inverse correlation between age at disease onset and anti-GluA3 antibody titer.
Figure 2. Brain atrophy in FTD patients with GluA3 antibodies. MRI scans were available in 18 FTD patients 
with anti-GluA3 antibodies (age: 62.4 ± 6.7, gender F: 38.9%) and were compared to 42 healthy controls (age: 
61.0 ± 9.1, gender F: 66.7%) (SPM12 software package Wellcome Department of Imaging Neuroscience, 
London; http://www.fil.ion.ucl.ac.uk/spm). Statistical threshold was set at p < 0.05, Family Wise Error (FWE) 
corrected, with a minimum cluster size of 50 voxels.
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It is well-known that AMPARs play a key role in the maintenance of dendritic spines at the glutamatergic syn-
apse22. Accordingly, we evaluated the effect of the reduction of synaptic GluA3-containing AMPARs on dendritic 
spine density (Fig. 4D,E). To perform this, rat primary hippocampal neurons were transfected with GFP at DIV8 
and incubated for 24 h with CSF+ or CSF− at DIV14. As shown in Fig. 4D,E, the presence of anti-GluA3 anti-
bodies induced a significant reduction of GFP-positive dendritic spines (***p < 0.001 one-way ANOVA; Tukey 
post hoc test, mock vs. CSF+ 1:100: ***p < 0.001, mock vs. CSF+ 1:20: ***p < 0.001, CSF+ 1:20 vs. CSF− 1:20: 
*p < 0.05, CSF+ 1:100 vs. CSF− 1:100: *p < 0.05). Again, CSF− did not induce any significant alteration of den-
dritic spines compared to mock neurons (Fig. 4D,E).
- Human iPSCs. Next, differentiated neurons obtained from hiPSCs were used to validate and substantiate 
results obtained in rat primary neuronal cultures. To do this, the hiPSC clones were tested to determine the 
expression of endogenous pluripotency markers (data not shown). The hiPSC clones were then differentiated 
into cortical neurons via the generation of neural-rosette intermediate neural progenitors, and they were subse-
quently differentiated for 80 days. Differentiated neurons were incubated with CSF+ and CSF− (1:100 dilution). 
After treatment, a biochemical fractionation approach was used to purify a triton-insoluble postsynaptic fraction 
(TIF)23 to be used for WB analysis. As shown in Fig. 5A–C, CSF+ led to a significant reduction of GluA3 levels in 
the synaptic fraction but not in the total cell homogenate, thus supporting the results obtained by confocal imag-
ing in rat neurons (**p < 0.01, GluA3 TIF CSF+ vs. GluA3 TIF CSF−). Conversely, treatment with CSF+ did not 
modify synaptic levels of the GluA1 subunit of the AMPARs or the levels of PSD-95, namely the most abundant 
protein in the excitatory postsynaptic density (Fig. 5A–C).
Finally, we explored the effect of either CSF+ or CSF− incubation on the key-players in FTD, namely Tau and 
TDP43. As shown in Fig. 6A–C, in the total cell homogenate of differentiated neurons obtained from hiPSCs, 
treatment with CSF+ lead to an increase of intracellular Tau expression levels as compared to treatment with 
CSF− (p = 0.017), whilst TDP43 levels were unchanged.
Discussion
Autoimmunity is a rapidly expanding field of the central nervous system disorders24. Autoantibodies to neuronal 
surface antigens have been described in association with autoimmune encephalopathies, which prominently fea-
ture psychiatric symptoms and behavioural disorders25. The potential role of these autoantibodies in primary 
dementia is of increasing interest13,26,27.
In the present paper, we reported for the first time the presence of concomitant autoimmune disorder in a 
significant number of FTD cases, defined by the presence of autoantibodies for the GluA3 subunit of AMPARs 
both in serum and CSF. In most of the cases, clinical presentations resemble those of bvFTD, with presenile onset, 
Figure 3. Cell-based assay in heterologous COS7 cell. Confocal imaging of COS7 cells transfected with rat 
GluA3-GFP (green) and incubated with a GluA3 commercial antibody (upper panels), CSF+ (middle panels) 
or CSF− (lower panels) for the staining of GluA3 (red). Dapi was used to recognize cell nuclei (blue). Merge 
panels are shown on the right. Scale bar, 10 μm.
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absence of autosomal dominant disorder, and greater bitemporal atrophy. Interestingly, however, antibody titer 
seem to correlate well with age at disease onset, with earlier symptom onset observed in those patients with higher 
antibody levels. However, the association between the presence or absence of anti-GluA3 antibodies and related 
clinical features is weak and needs further investigation. Furthermore, on the present study, we mainly considered 
serum anti-GluA3 peptide A antibodies, but these well correlated with CSF anti-GluA3 antibodies and serum 
anti-GluA3 peptide B antibodies, according to literature data15.
Figure 4. Neurobiological effect of GluA3 antibodies in primary rat neurons. (A) Fluorescence 
immunocytochemistry of GluA3 (green), PSD-95 (red) and MAP2 (blue) in DIV14 neurons treated with 
CSF with (CSF+) or without (CSF−) anti-GluA3 antibodies at two different dilutions (1:20 and 1:100) for 
24 hours. Scale bar, 5 μm. (B) Bar graph representing the percentage of co-localization of GluA3 with PSD-95. 
Data are presented as mean ± s.e.m, n = 14, one-way ANOVA followed by Tukey as post hoc test; *p < 0.05, 
**p < 0.01, ***p < 0.001. (C) Bar graph representing the density of GluA3 positive cluster along dendrites. 
Data are presented as mean ± s.e.m., n = 14, one-way ANOVA followed by Tukey as post hoc test. (D) Confocal 
images of rat primary hippocampal neurons transfected at DIV8 with GFP and immunolabeled at DIV14 for 
GFP (green). Scale bar: 5 μm. (E), Bar graph showing the quantification of dendritic spine density. Data are 
presented as mean ± s.e.m., n = 6–8, one-way ANOVA followed by Tukey as post hoc test; *p < 0.05, **p < 0.01, 
***p < 0.001.
Figure 5. Neurobiological effect of GluA3 antibodies in neurons differentiated from human iPSCs. (A) WB 
analysis from homogenates and triton-insoluble postsynaptic fractions (TIF) of neurons differentiated from 
human iPSC and incubated for 24 hours with CSF with (CSF+) or without (CSF−) anti-GluA3 antibodies 
(dilution 1:100). (B,C) The histogram shows the quantification of the expression levels of GluA3, GluA1 
and PSD-95 in homogenate (B) and TIF (C), normalized on tubulin and expressed as % of CSF−. N = 5 
***p < 0.001, unpaired Student’s t-test.
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AMPARs are tetrameric ligand-gated ion channels consisting of the subunits GluA1–4 and play a critical 
role in mediating fast excitatory neurotransmission. Excitatory glutamatergic synapses mainly express GluA1/
GluA2- and GluA2/GluA3-containing AMPARs forming channels that are impermeable to calcium. Notably, the 
main properties of AMPARs, including kinetics, ligand pharmacology, and membrane insertion/endocytosis are 
strictly regulated by the subunit composition28.
Several evidences have claimed for a possible role of AMPARs in FTD pathogenesis: (i) the hyperexcitability 
of AMPARs contribute to neurodegeneration29, (ii) in animal model of FTD, the social deficits were accompa-
nied by a change of AMPAR composition29; (iii) frontal cortex and hiPSCs of bvFTD patients showed changes of 
AMPARs30; and (iv) physiological release of Tau protein is mediated by AMPARs14.
In this work, we have now demonstrated that anti-GluA3 antibodies are able to modify AMPAR function. 
We extensively studied the biological role of anti-GluA3 antibodies both in rat hippocampal neuronal primary 
cultures and in human neurons derived from iPSCs. Overall, our results demonstrated that anti-GluA3 antibod-
ies lead to a reduction of the synaptic levels of GluA3-containing AMPARs both in rat primary neurons and in 
human neurons differentiated from iPSCs. In addition, the presence of GluA3 antibodies in the CSF is sufficient 
to induce a significant decrease of dendritic spine density, thus indicating that GluA3 antibodies can trigger not 
only a molecular event at receptor level but also a more profound morphological alteration of neuronal function.
Our molecular results are in accordance with previous studies performed by using anti-GluA1/GluA231 
and anti-NMDA antibodies32. Anti-GluA1 and anti-GluA2 antibodies led to a reduction of surface and synap-
tic of GluA1- and GluA2-containing AMPARs31. Similarly, in patients with encephalitis, anti-GluN1 antibodies 
induced progressive and selective decrease of synaptic NMDAR clusters32. However, the effect of anti-AMPAR 
antibodies on spine density and the capability of these antibodies to act similarly in neurons differentiated from 
hiPSCs were at present unknown.
Synaptic alterations are strongly correlated with cognitive impairment and memory decline in patients. It is 
known that AMPARs removal from synaptic sites is critical for this pathway to induce synaptic failure33. Notably, 
blocking AMPARs internalization has been shown to be sufficient to prevent dendritic spine loss. Moreover, in 
several neurological disorders, AMPAR function and AMPAR-dependent synaptic morphology are altered, thus 
making these receptors as possible pharmacological targets34,35.
At present, we cannot conclusively define whether the presence of anti-AMPA GluA3 receptor antibodies 
was the consequence of neuronal loss, able to further compromise the on-going neurodegenerative process, or 
otherwise a trigger event to protein misfolding. However, our data strongly indicate that the presence of these 
antibodies was detrimental for neurons and AMPAR function.
A further intriguing unanswered question is whether these antibodies are associated with a selective neu-
ropathological hallmark or not. As widely demonstrated by literature, demographic and clinical characteristics 
are not able to predict neuropathological features in FTD patients. In fact, excluding progranulin dosage, there 
are no biological biomarkers able to determine the presence of either Tau or TDP43 inclusions36. Accordingly, 
we did not find any significant clinical difference between FTD patients with or without anti-GluA3 antibodies. 
Neuroimaging data, with a relative symmetric and relative localised predominantly temporal involvement, might 
suggest Tau-related FTD in first instance36. Indeed, it has been demonstrated a direct link between Tau protein 
and AMPARs: the stimulation of neuronal activity by AMPAR activation induced Tau release from mature corti-
cal neurons in a calcium-dependent way. Tau secretion is therefore a regulatable process, dysregulation of which 
might contribute to the spread and intracellular accumulation of Tau pathology in disease14. The link between Tau 
and AMPARs was even mediated by Tau protein acetylation, able to impair AMPAR trafficking37. In this view, we 
found increased levels of Tau protein in neurons differentiated from hiPSCs treated with CSF with anti-GluA3 
antibodies, and we did not find any significant change in TDP43. However, these represent only preliminary find-
ings and further work on the relationship between AMPAR autoantibodies and autopsy data will be key.
Independently of neuropathological correlations and the still open question whether these antibodies were 
pathogenic or secondary to preceding neuronal damage, the co-presence of autoimmune process deserves atten-
tion. Autoimmune dementias are currently treatable disorders, by different immunosuppressive approaches24. 
In an orphan disorder, as FTD is, immunoglobulin administration and/or long-term rituximab or cyclophos-
phamine treatment might be claimed in those patients with anti-AMPA antibodies, to reverse or slow the neuro-
degenerative process.
Figure 6. Effect of GluA3 antibodies in neurons differentiated from human iPSc on Tau and TDP43 expression. 
(A) Representative WB analysis from homogenates of neurons differentiated from human iPSc and incubated 
for 24 hours with CSF with (CSF+) or without (CSF−) anti-GluA3 antibodies (dilution 1:100). (B,C) The 
histogram shows the quantification of the expression levels of Tau (B) and TDP43 (C), normalized on GAPDH; 
results are expressed as mean±standard errors (SEM), *p < 0.05, paired Student’s t-test.
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We acknowledge that the present preliminary study entails several limits. As mentioned before, autopsy cor-
relation analyses should be carried out and the screening for other autoantibodies likely affecting frontotem-
poral cortex, i.e. anti-NMDA antibodies, should be considered in future studies. A deeper characterisation of 
Tau processing and Tau protein abnormalities in cases with anti-GluA3 antibodies should also be performed. 
Furthermore, larger studies are needed to clearly establish the prevalence of FTD cases associated with autoim-
mune defect homeostasis.
In conclusion, at best of our knowledge, in this work we firstly provided strong evidence for an autoimmune 
aetiology in a significant proportion of FTD patients. This represents a novel molecular mechanism in FTD, 
which potentially might benefit of a proper treatment and might open new lights in the underpinnings of the 
disease.
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